



**Sterne Kessler
Goldstein Fox**

ATTORNEYS AT LAW



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugalsky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffery T. Helvey
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
W. Russell Swindell

Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Reginald D. Lucas
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Rodney G. Maze

Registered Patent Agents*
Karen R. Markowicz
Andrea J. Kamage
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
Jason D. Eisenberg
John J. Figueroa

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
•Practice Limited to
Federal Agencies

September 25, 2002

P# 71

WRITER'S DIRECT NUMBER:

(202) 371-2543

INTERNET ADDRESS:

AKAMAGE@SKGF.COM

Commissioner for Patents
Washington, D.C. 20231

Art Unit 1641

Re: U.S. Utility Patent Application
Appl. No. 09/977,283; Filed: October 16, 2001
For: **Composition and Method For Enhancing Fibrinolysis**
Inventor: Guy L. Reed
Our Ref: 0609.4320003/JAG/AJK

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449, 40 pages, listing 168 documents;
3. One copy of each of the 168 cited documents on Form PTO-1449; and
4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

RECEIVED
SEP 26 2002
TECH CENTER 1600/2900

Commissioner for Patents
September 25, 2002
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Andrea Jo Kamage
Agent for Applicants
Registration No. 43,703


JAG/AJK/jk
Enclosures

::ODMA\HODMA\SKGF_DC1;32436;1
SKGF Rev. 2/15/02 dcw

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Guy L. Reed

Appl. No. 09/977,283

Filed: October 16, 2001

For: **Composition and Method For
Enhancing Fibrinolysis**

Confirmation No. 2070

Art Unit: 1641

Examiner: *To Be Assigned*

Atty. Docket: 0609.4320003/JAG/AJK

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

The Examiner's attention is directed to the following co-pending U.S. Patent Application, which is directed to related technical subject matter: U.S. Patent Application No. 08/934,000, filed September 19, 1997, and submitted herewith as Document AS40.

The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to this application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language documents AT38 and AP3 cited on Form PTO 1449:

Document **AT38** is in a foreign language. An English language translation of document AT38 is attached as document **AT39**.

Document AP3 is in a foreign language. An English language abstract of document AP3 is attached as document **AS39**. Document AP3 appears to show a monoclonal antibody which binds to α 2-plasmin-inhibitors and inhibits the fibrinolysis inhibitory action of α 2-plasmin-inhibitor.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Andrea Jo Kamage
Agent for Applicant
Registration No. 43,703

Date: 9/25/02

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600



RECEIVED

SEP 26 2002

TECH CENTER 1608/2900

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	4,147,765	04/03/1979	Stephan et al.	424	12	07/16/1976
	AB1	4,198,335	04/15/1980	Collen	260	112	03/08/1977
	AC1	4,245,040	01/13/1981	Pilgeram	435	13	11/20/1978
	AD1	4,273,873	06/16/1981	Sugitachi et al.	435	180	10/25/1977
	AE1	4,346,029	08/24/1982	Collen	260	112	01/22/1979
	AF1	4,368,149	01/11/1983	Masuho et al.	260	112	12/16/1981
	AG1	4,414,148	11/08/1983	Jansen et al.	260	112	04/14/1982
	AH1	4,421,735	12/20/1983	Haber et al.	424	1.1	04/17/1980
	AI1	4,455,290	06/19/1984	Olexa et al.	424	1.1	04/02/1981
	AJ1	4,470,925	09/11/1984	Auditore-Hargreaves	260	112	10/04/1983
	AK1	4,474,893	10/02/1984	Reading	436	547	07/01/1981

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	EP 0 063 002 A2	10/20/1982	Europe			Yes No
	AM1	EP 0 088 994 A2	09/21/1983	Europe			Yes No
	AN1	WO 83/03678 A1	10/27/1983	PCT			Yes No
	AO1	WO 83/03679 A1	10/27/1983	PCT			Yes No
	AP1	WO 83/03971 A1	11/24/1983	PCT			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
AR	<u>1</u>	Agnelli, G., et al., "The Comparative Effects of Recombinant Hirudin (CGP 39393) and Standard Heparin on Thrombus Growth in Rabbits," <i>Thromb. Haemost.</i> 63:204-207, F.K. Schattauer Verlagsgesellschaft mbH (1990).	
AS	<u>1</u>	Agnelli, G., et al., "A Comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits," <i>Circulation</i> 72:178-182, American Heart Association, Inc. (1985).	
AT	<u>1</u>	Agnelli, G., et al., "Sustained Thrombolysis With DNA-Recombinant Tissue Type Plasminogen Activator in Rabbits," <i>Blood</i> 66:399-401, Grune and Stratton, Inc. (1985).	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 2 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA2	4,545,988	10/08/1985	Nakayama et al.	424	94	12/18/1984
	AB2	4,671,958	06/09/1987	Rodwell et al.	424	85	03/09/1982
	AC2	4,673,573	06/16/1987	Ferres et al.	424	94	01/09/1985
	AD2	4,722,903	02/02/1988	Kudryk et al.	435	7	01/03/1984
	AE2	4,758,524	07/19/1988	Bundesen et al.	436	548	03/15/1984
	AF2	4,833,085	05/23/1989	Schaumann et al.	435	240.27	08/13/1986
	AG2	4,916,070	04/10/1990	Matsueda et al.	435	172.2	04/14/1986
	AH2	4,927,916	05/22/1990	Matsueda et al.	530	387	01/30/1986
	AI2	5,116,613	05/26/1992	Haber et al.	424	85.8	01/08/1985
	AJ2	5,372,812	12/13/1994	Reed et al.	424	145.1	09/10/1992
	AK2	5,582,862	12/10/1996	Reed et al.	424	145.1	12/01/1992

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL2	AU-B-25387/84	09/20/1984	Australia			Yes No
	AM2	EP 0 120 694 A2	10/03/1984	Europe			Yes No
	AN2	EP 0 125 023 A1	11/14/1984	Europe			Yes No
	AO2	WO 85/00974 A1	03/14/1985	PCT			Yes No
	AP2	EP 0 142 905 A2	05/29/1985	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Angles-Cano, E.R., "Tissue plasminogen activator determination with a fibrin-supported film," Chem. Abstracts 104:307-308, Abstract No. 144639d, American Chemical Society (1986).
	AS	2	Aoki, N., et al., "Fibrin-Associated Plasminogen Activation in α_2 -Plasmin Inhibitor Deficiency," Blood 62:1118-1122, Grune and Stratton, Inc. (1983).
	AT	2	Bates, E.R., et al., "A Monoclonal Antibody Against the Platelet Glycoprotein IIb/IIIa Receptor Complex Prevents Platelet Aggregation and Thrombosis in a Canine Model of Coronary Angioplasty," Circulation 84:2463-2469, American Heart Association, Inc. (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 3 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJK

APPLICATION NO.
09/977,283

APPLICANT
Reed

FILING DATE
October 16, 2001

GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA3	5,585,089	12/17/1996	Queen et al.	424	133.1	06/07/1995
	AB3	5,831,031	11/03/1998	Reed et al.	530	388.1	07/16/1996
	AC3	6,114,506	09/05/2000	Reed et al.	530	387.3	09/19/1997
	AD3	6,280,730 B1	08/28/2001	Reed et al.	424	141.1	11/24/1997
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	EP 0 146 050 A2	06/26/1985	Europe			Yes No
	AM3	EP 0 159 025 A2	10/23/1985	Europe			Yes No
	AN3	WO 86/01533 A1	03/13/1986	PCT			Yes No
	AO3	EP 0 187 658 A2	07/16/1986	Europe			Yes No
	AP3	JP 61-268630	11/28/1986	Japan			Yes No X


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Bode, C., et al., "Conjugation to Antifibrin Fab' Enhances Fibrinolytic Potency of Single-Chain Urokinase Plasminogen Activator," <i>Circulation</i> 81:1974-1980, American Heart Association, Inc. (1990).
	AS	<u>3</u>	Bode, C., et al., "Antibody-Directed Urokinase: A Specific Fibrinolytic Agent," <i>Science</i> 229:765-767, American Association for the Advancement of Science (1985).
	AT	<u>3</u>	Bode, C., et al., "Thrombolysis by a Fibrin-specific Antibody Fab'-Urokinase Conjugate," <i>J. Mol. Cell. Cardiol.</i> 19:335-341, Academic Press, Inc. (1987).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 4 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL4	WO 87/05934 A1	10/08/1987	WIPO			Yes No
	AM4	WO 87/06263 A1	10/22/1987	WIPO			Yes No
	AN4	WO 88/01649 A1	03/10/1988	WIPO			Yes No
	AO4	WO 88/03559 A1	05/19/1988	WIPO			Yes No
	AP4	EP 0 271 227 A2	06/15/1988	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>4</u>	Bode, C., et al., "Antibody-directed Fibrinolysis. An Antibody Specific For Both Fibrin and Tissue Plasminogen Activator," <i>J. Biol. Chem.</i> 264:944-948, American Society for Biochemistry and Molecular Biology, Inc. (1989).
	AS	<u>4</u>	Boulianne, G.L., et al., "Production of functional chimaeric mouse/human antibody," <i>Nature</i> 312:643-646, Macmillan Journals Ltd. (1984).
	AT	<u>4</u>	Branscomb, E.E., et al., "Bispecific Monoclonal Antibodies Produced by Somatic Cell Fusion Increase the Potency of Tissue Plasminogen Activator," <i>Thromb. Haemost.</i> 64:260-266, F.K. Schattauer Verlagsgesellschaft mbH (1990).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 5 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL5	EP 0 336 693 A2	10/11/1989	Europe			Yes No
	AM5	WO 89/09817 A1	10/19/1989	WIPO			Yes No
	AN5	WO 91/09967 A1	07/11/1991	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>5</u>	Brennan, M., et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G ₁ Fragments," <i>Science</i> 229:81-83, American Association for the Advancement of Science (1985).
	AS	<u>5</u>	Butte, A.N., et al., " α_2 -Antiplasmin Causes Thrombi to Resist Fibrinolysis Induced by Tissue Plasminogen Activator in Experimental Pulmonary Embolism," <i>Circulation</i> 95:1886-1891, American Heart Association, Inc. (April 1997).
	AT	<u>5</u>	Carrasquillo, J.A., et al., "Radioimmunodetection of Human Melanoma with Monoclonal Antibodies and Fab Fragments," in: <i>Radioimmunoimaging and Radioimmunotherapy</i> , Burchiel, S. and Rhodes, B., eds., Elsevier Science Publishing Co., Inc., Amsterdam, The Netherlands, pp. 357-368 (1983).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 6 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>6</u>	Charpie, J.R., et al., "A Bispecific Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase," <i>Biochemistry</i> 29:6374-6378, American Chemical Society (1990).
	AS	<u>6</u>	Collen, D., et al., "Thrombolysis with Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits with Experimental Jugular Vein Thrombosis," <i>J. Clin. Invest.</i> 71:368-376, Rockefeller University Press (1983).
	AT	<u>6</u>	Collen, D., et al., "Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue-Type and Urokinase-Type Plasminogen Activators," <i>Circulation</i> 84:1216-1234, American Heart Association, Inc. (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 7 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>7</u>	Collen, D., et al., "Synergism of thrombolytic agents in vivo," <i>Circulation</i> 74:838-842, American Heart Association, Inc. (1986).
	AS	<u>7</u>	DeWood, M.A., et al., "Prevalence of Total Coronary Occlusion During the Early Hours of Transmural Myocardial Infarction," <i>New Engl. J. Med.</i> 303:897-902, Massachusetts Medical Society (1980).
	AT	<u>7</u>	Dorai, H. and Moore, G.P., "The Effect of Dihydrofolate Reductase-Mediated Gene Amplification on the Expression of Transfected Immunoglobulin Genes," <i>J. Immunol.</i> 139:4232-4241, American Association of Immunologists (1987).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SEP 26 2002

TECH CENTER 1600/2900

Page 8 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>8</u>	Duberstein, R., "Scientists Develop New Technique for Producing Bispecific Monoclonals," <i>Genetic Engineering News</i> 6:22-24, Mary Ann Liebert, Inc. (1986).
	AS	<u>8</u>	Emeis, J.J. and Verheijen, J.H., "Thrombolytic Properties in a Rabbit Jugular Vein Thrombosis Model of a Tissue-type Plasminogen Activator Mutant Lacking the Growth Factor- and Kringle One-Domains," <i>Arzneim.-Forsch./Drug Res.</i> 42:358-362, Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH (1992).
	AT	<u>8</u>	Fisher, R., et al., "Isolation and Characterization of the Human Tissue-type Plasminogen Activator Structural Gene Including Its 5' Flanking Region," <i>J. Biol. Chem.</i> 260:11223-11230, American Association of Biological Chemists, Inc. (1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 9 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>9</u>	Gardell, S.J., et al., "Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits," <i>Circulation</i> 84:244-253, American Heart Association, Inc. (1991).
	AS	<u>2</u>	Gold, H.K., et al., "Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion," <i>Circulation</i> 73:347-352, American Heart Association, Inc. (February 1986).
	AT	<u>2</u>	Haber, E., et al., "Antibody Targeting as a Thrombolytic Strategy," <i>Ann. N.Y. Acad. Sci.</i> 667:365-381, New York Academy of Sciences (1992).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 10 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Harris, W.J. and Emery, S., "Therapeutic antibodies - the coming of age," <i>Trends Biotechnol.</i> 11:42-44, Elsevier Science Publishers Ltd. (1993).
	AS	<u>10</u>	Hatley, E., et al., "Monoclonal Antibodies Against Plasminogen and Alpha-2-Antiplasmin: Binding to Native and Modified Antigens," <i>Thrombosis Res.</i> 45:485-495, Pergamon Journals Ltd. (1987).
	AT	<u>10</u>	Hessel, B., et al., "Primary Structure of Human Fibrinogen and Fibrin. Structural Studies on NH ₂ -terminal Part of B β Chain," <i>Eur. J. Biochem.</i> 98:521-534, Springer Verlag (1979).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SEP 26 2002

TECH CENTER 1600/2900

Page 11 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Houranieh, A., et al., "Monoclonal Antibodies to Human Cross-Linked Fibrin," <i>Fed. Proc.</i> 44:1846, Abstract No. 8381, Federation of American Societies for Experimental Biology (1985).
	AS	<u>11</u>	Hui, K.Y., et al., "Immunodetection of Human Fibrin Using Monoclonal Antibody-64C5 in an Extracorporeal Chicken Model," <i>Thromb. Haemost.</i> 54:524-527, F.K. Schattauer Verlag GmbH (1985).
	AT	<u>11</u>	Hui, K.Y., et al., "Monoclonal Antibodies of Predetermined Specificity for Fibrin: A Rational Approach to Monoclonal Antibody Production," <i>Hybridoma</i> 5:215-222, Mary Ann Liebert, Inc. (1986).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 12 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJK

APPLICATION NO.
09/977,283

APPLICANT
Reed

FILING DATE
October 16, 2001

GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Hui, K.Y., et al., "Monoclonal Antibodies to a Synthetic Fibrin-Like Peptide Bind to Human Fibrin but Not Fibrinogen," <i>Science</i> 222:1129-1132, American Association for the Advancement of Science (1983).
	AS	<u>12</u>	Ito, R.K., et al., "Fibrinolysis Studies: Fibrinogen-Specific Antibody as Carriers for Fibrinolytic Agents," <i>Fed. Proc.</i> 44:1846, Abstract No. 8382, Federation of American Societies for Experimental Biology (1985).
	AT	<u>12</u>	Jones, P.T., et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> 321:522-525, Macmillan Journals Ltd. (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 13 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>13</u>	Kabnick, K.S. and Housman, D.E., "Determinants That Contribute to Cytoplasmic Stability of Human c-fos and β -Globin mRNAs Are Located at Several Sites in Each mRNA," <i>Mol. Cell. Biol.</i> 8:3244-3250, American Society for Microbiology (1988).
	AS	<u>13</u>	Kato, K., et al., "A specific immunoassay system for hybrid type antigens," <i>Chem. Abstracts</i> 94:325, Abstract No. 61048j, American Chemical Society (1981).
	AT	<u>13</u>	Kimura, S., et al., "Acceleration of Fibrinolysis by the N-Terminal Peptide of α_2 -Plasmin Inhibitor," <i>Blood</i> 66:157-160 Grune and Stratton, Inc. (1985).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>14</u>	Kudryk, B., et al., "A Monoclonal Antibody With Ability to Distinguish Between NH ₂ -Terminal Fragments Derived From Fibrinogen and Fibrin," <i>Mol. Immunol.</i> 20:1191-1200, Pergamon Press Ltd. (1983).
	AS	<u>14</u>	Kudryk, B., et al., "Specificity of a Monoclonal Antibody for the NH ₂ -Terminal Region of Fibrin," <i>Mol. Immunol.</i> 21:89-94, Pergamon Press Ltd. (1984).
	AT	<u>14</u>	Kumada, T. and Abiko, Y., "Physiological Role of α_2 -Plasmin Inhibitor in Rats," <i>Thrombosis Res.</i> 36:153-163, Pergamon Press Ltd. (1984).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 15 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>15</u>	Laffel, G.L. and Braunwald, E., "Thrombolytic Therapy. A New Strategy for the Treatment of Acute Myocardial Infarction (First of Two Parts)," <i>New England J. Med.</i> 311:710-717, Massachusetts Medical Society (1984).
	AS	<u>15</u>	Laffel, G.L. and Braunwald, E., "Thrombolytic Therapy. A New Strategy for the Treatment of Acute Myocardial Infarction (Second of Two Parts)," <i>New England J. Med.</i> 311:770-776, Massachusetts Medical Society (1984).
	AT	<u>15</u>	Lanzavecchia, A. and Scheidegger, D., "The use of hybrid hybridomas to target human cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> 17:105-111, VCH Verlagsgesellschaft mbH (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 16 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Larsen, G.R., et al., "Protein Engineering of Novel Plasminogen Activators with Increased Thrombolytic Potency in Rabbits Relative to Activase," <i>J. Biol. Chem.</i> 266:8156-8161, American Society for Biochemistry and Molecular Biology, Inc. (1991).
	AS	<u>16</u>	Lawn, R.M., et al., "The Nucleotide Sequence of the Human β -Globin Gene," <i>Cell</i> 21:647-651, Massachusetts Institute of Technology (1980).
	AT	<u>16</u>	Lijnen, H.R., et al., "Comparative Fibrinolytic Properties of Staphylokinase and Streptokinase in Animal Models of Venous Thrombosis," <i>Thromb. Haemost.</i> 66:468-473, F.K. Schattauer Verlagsgesellschaft mbH (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

SEP 26 2002

TECH CENTER 1600/2900

Page 17 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Lijnen, H.R., et al., "Biochemical and Thrombolytic Properties of a Low Molecular Weight Form (Comprising Leu ¹⁴⁴ through Leu ⁴¹¹) of Recombinant Single-chain Urokinase-type Plasminogen Activator," <i>J. Biol. Chem.</i> 263:5594-5598, American Society for Biochemistry and Molecular Biology, Inc. (1988).
	AS	<u>17</u>	Liu, M.A., et al., "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> 82:8648-8652, National Academy of Sciences (1985).
	AT	<u>17</u>	Love, T.W., et al., "Recombinant Antibodies Possessing Novel Effector Functions," <i>Meth. Enzymol.</i> 178:515-527, Academic Press, Inc. (1989).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 18 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Lukacova, D., et al., "Inhibition of Factor XIII Activation by an Anti-Peptide Monoclonal Antibody," <i>Biochemistry</i> 30:10164-10170, American Chemical Society (1991).
	AS	<u>18</u>	Martin, U., et al., "Properties of a novel plasminogen activator (BM 06.022) produced in <i>Escherichia coli</i> ," <i>Z. Kardiol.</i> 79 Suppl. 3:167-170, Dr. Dietrich Steinkopff Verlag (1990).
	AT	<u>18</u>	Matsueda, G.R., et al., "A Monoclonal Antibody Specific for the C Terminus of Fibrinogen and Fibrin Gamma Chains," <i>FASEB J.</i> 2:A1411, Abstract No. 6480, Federation of American Societies for Experimental Biology (1988).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 19 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>19</u>	Matsueda, G.R., et al., "Fibrin-Specific Monoclonal Antibodies are Elicited by Immunization with a Synthetic Fibrin-Like Peptide," in: <i>Fibrinogen: Structural Variants and Interactions</i> , Volume 3, Henschen, A., et al., eds., Walter de Gruyter, Berlin, Germany, pp. 43-50 (1985).
	AS	<u>19</u>	Matsueda, G.R., et al., "Monoclonal Antibodies Specific for Human Fibrin Monomer," <i>Fed. Proc.</i> 42:1992, Abstract No. 1375, Federation of American Societies for Experimental Biology (1983).
	AT	<u>19</u>	Matsueda, G.R., et al., "Detection of Thrombi: A Chicken Model Using Monoclonal Antibody Which Binds to Human Fibrin but Not Fibrinogen," <i>Haemostasis</i> 14:44, Abstract No. 75, S. Karger AG (1984).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SEP 26 2002

TECH CENTER 1600/2900

Page 20 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>20</u>	Matsueda, G.R., et al., "Synthetic Fibrin-Like Peptides Used as Antigens Yield Fibrin-Specific Antibodies," in: <i>Peptides: Structure and Function, Proceedings of the Eighth American Peptide Symposium</i> , Hruby, V.J. and Rich, D.H., eds., Pierce Chemical Company, Rockford, IL pp. 873-876 (1983).
	AS	<u>20</u>	Matsuo, O., et al., "Thrombolytic Effect of Single-Chain Pro-Urokinase in a Rabbit Jugular Vein Thrombosis Model," <i>Thrombosis Res.</i> 42:187-194, Pergamon Press Ltd. (1986).
	AT	<u>20</u>	Matsuo, O., et al., "Comparison of the Relative Fibrinogenolytic, Fibrinolytic and Thrombolytic Properties of Tissue Plasminogen Activator and Urokinase in Vitro," <i>Thromb. Haemost.</i> 45:225-229 F.K. Schattauer Verlagsgesellschaft mbH (1981).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SEP 26 2002

TECH CENTER 1600/2900

Page 21 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>21</u>	McCabe, R.P., et al., "A Diagnostic-Prognostic Test for Bladder Cancer Using a Monoclonal Antibody-based Enzyme-linked Immunoassay for Detection of Urinary Fibrin(ogen) Degradation Products," <i>Cancer Res.</i> 44:5886-5893, American Association for Cancer Research (1984).
	AS	<u>21</u>	Miles, L.A., et al., "A Bleeding Disorder Due to Deficiency of α_2 -Antiplasmin," <i>Blood</i> 59:1246-1251, Grune and Stratton, Inc. (1982).
	AT	<u>21</u>	Milstein, C. and Cuello, A.C., "Hybrid hybridomas and their use in immunohistochemistry," <i>Nature</i> 305:537-540, Macmillan Magazines Ltd. (1983).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 22 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>22</u>	Mimuro, J., et al., "Monoclonal Antibodies to Discrete Regions in α_2 -Plasmin Inhibitor," <i>Blood</i> 69:446-453, Grune and Stratton, Inc. (1987).
	AS	<u>22</u>	Morrison, S.L. and Oi, V.T., "Genetically Engineered Antibody Molecules," <i>Adv. Immunol.</i> 44:65-92, Academic Press, Inc. (1989).
	AT	<u>22</u>	Morrison, S.L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> 229:1202-1207, American Association for the Advancement of Science (1985).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2000 Page 23 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>23</u>	Morrison, S.L., et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," <i>Proc. Natl. Acad. Sci. USA</i> 81:6851-6855, National Academy of Sciences (1984).
	AS	<u>23</u>	Munro, A., "Uses of chimaeric antibodies," <i>Nature</i> 312:597, Macmillan Journals Ltd. (1984).
	AT	<u>23</u>	Neuberger, M.S., et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> 312:604-608, Macmillan Journals Ltd. (1984).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 24 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	24	Neuberger, M.S., et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," <i>Nature</i> 314:268-270, Macmillan Journals Ltd. (1985).
	AS	24	Nisonoff, A. and Mandy, W.J., "Quantitative Estimation of the Hybridization of Rabbit Antibodies," <i>Nature</i> 194:355-359, Macmillan Journals Ltd. (1962).
	AT	24	Nossel, H. L., "Relative proteolysis of the fibrinogen B β chain by thrombin and plasmin as a determinant of thrombosis," <i>Nature</i> 291:165-167, Macmillan Journals Ltd. (1981).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 25 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>25</u>	Oi, V.T. and Morrison, S.L. "Chimeric Antibodies," <i>BioTechniques</i> 4:214-221, Eaton Publishing Co. (1986).
	AS	<u>25</u>	Pacella, B.L., et al., "Induction of Fibrin-Specific Antibodies by Immunization with Synthetic Peptides That Correspond to Amino Termini of Thrombin Cleavage Sites," <i>Mol. Immunol.</i> 20:521-527, Pergamon Press Ltd. (1983).
	AT	<u>25</u>	Philpott, G.W., et al., "Selective Cytotoxicity of Hapten-Substituted Cells With an Antibody-Enzyme Conjugate," <i>J. Immunol.</i> 111:921-929, Williams and Wilkins Co. (1973).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 26 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>26</u>	Philpott, G.W., et al., "Selective Binding and Cytotoxicity of Rat Basophilic Leukemia Cells (RBL-1) with Immunoglobulin E-Biotin and Avidin-Glucose Oxidase Conjugates," <i>J. Immunol.</i> 125:1201-1209, Williams and Wilkins Co. (1980).
	AS	<u>26</u>	Pizzo, S.V., et al., "The Effect of Plasmin on the Subunit Structure of Human Fibrin," <i>J. Biol. Chem.</i> 248:4574-4583, American Society of Biological Chemists, Inc. (1973).
	AT	<u>26</u>	Plow, E.F., et al., "Changes in Antigenic Structure and Conformation of α_2 -Antiplasmin Induced by Interaction with Plasmin," <i>J. Biol. Chem.</i> 255:2902-2906, American Society of Biological Chemists, Inc. (1980).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 27 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>27</u>	Rajagopalan, S., et al., "A Nonantigenic Covalent Streptokinase-Polyethylene Glycol Complex with Plasminogen Activator Function," <i>J. Clin. Invest.</i> 75:413-419, Rockefeller University Press, Inc. (1985).
	AS	<u>27</u>	Reed, G.L., et al., "Acceleration of Plasma Clot Lysis by an Antibody to α_2 -Antiplasmin," <i>Trans. Assoc. Am. Phys.</i> 101:250-256, Waverly Press (1988).
	AT	<u>27</u>	Reed, G.L., et al., "Selective Inhibition of α_2 -Antiplasmin Augments the Potency and Specificity of Plasminogen Activators," <i>J. Am. Coll. Cardiol.</i> 13:2A, Elsevier Science (1989).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 1 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	28	Reed, G.L., et al., "Synergistic fibrinolysis: Combined effects of plasminogen activators and an antibody that inhibits α_2 -antiplasmin," <i>Proc. Natl. Acad. Sci. USA</i> 87:1114-1118, National Academy of Sciences (1990).
	AS	28	Reed, G.L., et al., "Inhibition of Clot-Bound α_2 -Antiplasmin Enhances In Vivo Thrombolysis," <i>Circulation</i> 82:164-168, American Heart Association, Inc. (1990).
	AT	28	Reed, G.L., "Functional Characterization of Monoclonal Antibody Inhibitors of α_2 -Antiplasmin that Accelerate Fibrinolysis in Different Animal Plasmas," <i>Hybridoma</i> 16:281-286, Mary Ann Liebert, Inc. (June 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



SEP 26 2002

TECH CENTER 1600/2900

Page 29 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>29</u>	Reed, G.L., " Monoclonal Antibodies: 77 (anti α 2 antiplasmin)," <i>Hybridoma</i> 16:392, Mary Ann Liebert, Inc. (August 1997).
	AS	<u>29</u>	Rosebrough, S.F., et al., "Radioimmunoimaging of Venous Thrombi Using Iodine-131 Monoclonal Antibody," <i>Radiology</i> 156:515-517, Radiological Society of North America, Inc. (1985).
	AT	<u>29</u>	Runge, M.S., et al., "Antibody-Enhanced Thrombolysis: Capture of Tissue Plasminogen Activator by a Bispecific Antibody and Direct Targeting by an Antifibrin-Tissue Plasminogen Activator Conjugate <i>In Vivo</i> ," <i>Trans. Assoc. Am. Phys.</i> 100:250-255, Waverly Press (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



● RECEIVED

SEP 26 2002

Page 30 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK		TECH CENTER 1600/2900 09/977,283
	APPLICANT Reed		
	FILING DATE October 16, 2001		GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>30</u>	Runge, M.S., et al., "Conjugation to an Antifibrin Monoclonal Antibody Enhances the Fibrinolytic Potency of Tissue Plasminogen Activator in Vitro," <i>Biochemistry</i> 27:1153-1157, American Chemical Society (1988).
	AS	<u>30</u>	Runge, M.S., et al., "Increasing Selectivity of Plasminogen Activators with Antibodies," <i>Clin. Res.</i> 36:501-506, American Federation for Clinical Research (1988).
	AT	<u>30</u>	Runge, M.S., et al., "Antibody-enhanced thrombolysis: Targeting of tissue plasminogen activator in vivo," <i>Proc. Natl. Acad. Sci. USA</i> 84:7659-7662, National Academy of Sciences (1987).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2800 1 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>31</u>	Runge, M.S., et al., "Antibody-Directed Fibrinolysis: A Bispecific (Fab') ₂ That Binds to Fibrin and Tissue Plasminogen Activator," <i>Bioconj. Chem.</i> 1:274-277, American Chemical Society (1990).
	AS	<u>31</u>	Sakata, Y. and Aoki, N., "Significance of Cross-Linking of α_2 -Plasmin Inhibitor to Fibrin in Inhibition of Fibrinolysis and in Hemostasis," <i>J. Clin. Invest.</i> 69:536-542, Rockefeller University Press, Inc. (1982).
	AT	<u>31</u>	Scheefers-Borchel, U., et al., "Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide," <i>Proc. Natl. Acad. Sci. USA</i> 82:7091-7095, National Academy of Sciences (1985).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**RECEIVED**

SEP 26 2002

TECH CENTER 1600/2900

Page 32 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>32</u>	Schnee, J.M., et al., "Construction and expression of a recombinant antibody-targeted plasminogen activator," <i>Proc. Natl. Acad. Sci. USA</i> 84:6904-6908, National Academy of Sciences (1987).
	AS	<u>32</u>	Sevilla, C.L., et al., "Plasminogen Activator-Anti-Human Fibrinogen Conjugate," <i>Fed. Proc.</i> 44:1073, Abstract No. 3872, Federation of Americans Societies for Experimental Biology (1985).
	AT	<u>32</u>	Sevilla, C.L., et al., "Plasminogen Activator-Anti-Human Fibrinogen Conjugate," <i>Biochem. Biophys. Res. Commun.</i> 130:91-96, Academic Press, Inc. (1985).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900 Page 33 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	33	Sharma, G.V.R.K., et al., "Medical Intelligence: Drug Therapy. Thrombolytic Therapy," <i>N. Engl. J. Med.</i> 306:1268-1276, Massachusetts Medical Society (1982).
	AS	33	Sharon, J., et al., "Expression of a V _H C _K chimaeric protein in mouse myeloma cells," <i>Nature</i> 309:364-367, Macmillan Journals Ltd. (1984).
	AT	33	Sobel, B.E., et al., "Augmented and Sustained Plasma Concentraions After Intramuscular Injections of Molecular Variants and Deglycosylated Forms of Tissue-Type Plasminogen Activators," <i>Circulation</i> 81:1362-1373, American Heart Association, Inc. (1990).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



TECH CENTER 1600/2900

Page 34 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>34</u>	Sobel, J.H., et al., "Characterization of a Crosslink-Containing Fragment Derived from the α Polymer of Human Fibrin and Its Application in Immunologic Studies using Monoclonal Antibodies," <i>Thrombos. and Haemostas.</i> 46:240, Abstract No. 0758, F.K. Schattauer Verlagsgesellschaft mbH (1981).
	AS	<u>34</u>	Soe, G., et al., "A rapid latex immunoassay for the detection of plasmin- α_2 -plasmin inhibitor complex. Utilization of two monoclonal antibodies differentially recognizing respective components of the complex," <i>Blood Coagulation and Fibrinolysis</i> 6:249-258, Rapid Communications of Oxford Ltd. (May 1995).
	AT	<u>34</u>	Soria, J., et al., "Monoconal Antibodies that React Preferentially With Fibrinogen Degradation Products or With Cross-Linked Fibrin Split Products," <i>Ann. N.Y. Acad. Sci</i> 408:665-666, New York Academy of Sciences (1983).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 35 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>35</u>	Staerz, U.D. and Bevan, M.J., "Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity," <i>Proc. Natl. Acad. Sci. USA</i> 83:1453-1457, National Academy of Sciences (1986).
	AS	<u>35</u>	Stump, D.C., et al., "Comparative Thrombolytic Properties of Single-Chain Forms of Urokinase-Type Plasminogen Activator," <i>Blood</i> 69:592-596, Grune and Stratton, Inc. (1987).
	AT	<u>35</u>	Sumi, Y., et al., "Structure of the Carboxyl-Terminal Half of Human α_2 -Plasmin Inhibitor Deduced from That of cDNA," <i>J. Biochem.</i> 100:1399-1402, Japanese Biochemical Society (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 36 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>36</u>	Thorpe, R., et al., "Single Shot Intrasplenic Immunization: An Advantageous Procedure for Production of Monoclonal Antibodies Specific for Human Fibrin Fragments," <i>Hybridoma</i> 3:381-385, Mary Ann Liebert, Inc. (1984).
	AS	<u>36</u>	Tucker, P.W., et al., "Sequence of the Cloned Gene for the Constant Region of Murine γ 2b Immunoglobulin Heavy Chain," <i>Science</i> 206:1303-1306, American Association for the Advancement of Science (1979).
	AT	<u>36</u>	van Zonneveld, A.-J., et al., "Structure and Function of Human Tissue-Type Plasminogen Activator (t-PA)," <i>J. Cell. Biochem.</i> 32:169-178, Alan R. Liss, Inc. (1986).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 37 of 40



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>37</u>	Verde, P., et al., "Identification and primary sequence of an unspliced human urokinase poly(A) ⁺ RNA," <i>Proc. Natl. Acad. Sci. USA</i> 81:4727-4731, National Academy of Sciences (1984).
	AS	<u>37</u>	Waldmann, T.A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> 252:1657-1662, American Association for the Advancement of Science (1991).
	AT	<u>37</u>	Whitaker, A.N., et al., "Measurement of Crosslinked Fibrin Degradation Products Using Monoclonal Antibodies: Use in the Study of Intravascular Coagulation," <i>Pathology</i> 16:357-358, Haematology and Blood Society of Australia (1984).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 38 of 40

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>	ATTY. DOCKET NO. 0609.4320003/JAG/AJK	APPLICATION NO. 09/977,283
	APPLICANT Reed	
	FILING DATE October 16, 2001	GROUP 1641

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>38</u>	Williams, G.T. and Neuberger, M.S., "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I klenow fragment," <i>Gene</i> 43:319-324, Elsevier Science Publishers (1986).
	AS	<u>38</u>	Wiman, B., et al., "Determination of plasmin- α_2 -antiplasmin complex in plasma samples by means of a radioimmunoassay," <i>Scand. J. Clin. Lab. Invest.</i> 43:27-33, Blackwell Scientific Publishers (1983).
	AT	<u>38</u>	Wojta, J., et al., "Anwendung monoklonaler Antikörper in der Fibrinolyse diagnostik," <i>Wiener klinische Wochenschrift</i> 97:244-248, Springer-Verlag (1985).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

Page 39 of 40

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>39</u>	Zamarron, C., et al., "Influence of Exogenous and Endogenous Tissue-Type Plasminogen Activator on the Lysability of Clots in a Plasma Milieu In Vitro," <i>Thrombosis Res.</i> 35:335-345, Pergamon Press Ltd. (1984).
	AS	<u>39</u>	English language abstract of Japanese Patent No. 61-268630, WPI Acc. No. 87-010915/02.
	AT	<u>39</u>	English Language Translation of Wojta, J., et al., Cyber Trans International Inc. (Reference No. AT38) (May 1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
0609.4320003/JAG/AJKAPPLICATION NO.
09/977,283APPLICANT
ReedFILING DATE
October 16, 2001GROUP
1641**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>40</u>	Declaration under 37 C.F.R. § 1.132 of Dr. Guy L. Reed, submitted on August 10, 1992 in U.S. Application No. 07/589,003, filed September 27, 1990 (Abandoned), a file-wrapper continuation of 07/589,003 was filed September 10, 1992 and given U.S. Application No. 07/943,372, now U.S. Patent No. 5,372,812, issued December 13, 1994, pp 5.
	AS	<u>40</u>	Pending Non-Provisional U.S. Patent Application No. 08/934,000, Reed, G.L., filed September 19, 1997.
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.